Table 1 Baseline characteristics of patients and study eyes

Mean (SD) age, years

72.6 (10.3)

71.7 (11.2)

0.515

 Range

39–91

39–94

Sex, n (%)

0.266

 Female

44 (52.4)

122 (59.5)

 Male

40 (47.6)

83 (40.5)

Race/Ethnicity, n (%)

0.007

 White

34 (40.5)

108 (52.7)

 Black

2 (2.4)

7 (3.4)

 Asian

6 (7.1)

1 (0.5)

 Other

0 (0.0)

1 (0.5)

 Not recorded in chart

42 (50.0)

88 (42.9)

Diagnosis, n (%)

0.671

 BRVO

44 (52.4)

113 (55.1)

 CRVO

40 (47.6)

92 (44.9)

Mean (SD) duration of ME, months

25.6 (26.4)

15.5 (21.4)

<0.001

 Range

0–100

0–150

Previous treatment for RVO, n (%)

70 (83.3)

178 (86.8)

0.439

  Intravitreal anti-VEGF, n (%)

51 (60.7)

154 (75.1)

0.014

    Bevacizumab

44 (52.4)

137 (66.8)

    Ranibizumab

11 (13.1)

29 (14.1)

    Pegaptanib

0 (.0)

3 (1.5)

    Ranibizumab and/or bevacizumab

51 (60.7)

152 (74.1)

    Mean (SD) number of ranibizumab and/or bevacizumab injections in these patients

5.2 (4.6)

4.5 (5.1)

0.383

  Intravitreal triamcinolone, n (%)

44 (52.4)

71 (34.6)

0.005

  Laser photocoagulation, n (%)

43 (51.2)

69 (33.7)

0.005

    Focal

33 (39.3)

52 (25.4)

0.018

    Panretinal

15 (17.9)

30 (14.6)

0.493

  Pars plana vitrectomy, n (%)

12 (14.3)

25 (12.2)

0.629

Glaucoma or OHT at baseline, n (%)

0.438

 Yes

27 (32.1)

64 (31.2)

 No

40 (47.6)

111 (54.1)

 Not recorded in chart

17 (20.2)

30 (14.6)

Using IOP-lowering medication at baseline, n (%)

20 (23.8)

54 (26.3)

0.505

History of IOP response to steroid, n (%)

0.065

 Yes

12 (14.3)

33 (16.1)

 No

42 (50.0)

126 (61.5)

 Not recorded in chart

30 (35.7)

46 (22.4)

Lens status, n (%)

0.069

 Phakic

29 (34.5)

99 (48.3)

 Pseudophakic

54 (64.3)

104 (50.7)

 Not recorded in chart

1 (1.2)

2 (1.0)

Mean (SD) BCVA, lines

9.1 (4.7)

10.1 (4.6)

0.095

 Snellen

20/125

20/100

Mean (SD) CRT, μm

465 (177)

427 (183)

0.136